| Code | CSB-RA004910MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Varlilumab, designed for research targeting CD27, a member of the tumor necrosis factor receptor superfamily. CD27 is a costimulatory molecule expressed on T cells, B cells, and NK cells that plays a critical role in regulating immune cell activation, differentiation, and survival. Upon binding to its ligand CD70, CD27 enhances T cell priming, promotes memory T cell generation, and supports antitumor immunity. Dysregulation of the CD27-CD70 pathway has been implicated in various hematological malignancies, autoimmune disorders, and solid tumors, making it an important target for immunological research.
Varlilumab, the reference antibody, is an investigational agonistic monoclonal antibody that stimulates CD27 signaling to enhance immune responses against cancer. This biosimilar provides researchers with a reliable tool for investigating CD27-mediated immune mechanisms, exploring T cell costimulation pathways, and evaluating potential immunotherapeutic strategies in oncology and immunology studies. It serves as a valuable reagent for in vitro and in vivo research applications focused on understanding immune regulation and developing novel therapeutic approaches.
There are currently no reviews for this product.